(PCYC) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 20, 2013
(Stock Blog Hub,
4/21/13)
Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase III study, RESONATE-2, which is being conducted to evaluate ibrutinib as a monotherapy versus...(read more)
(Stock Blog Hub,
8/28/12)
Pharmacyclics, Inc. (PCYC) recently announced the enrollment of the fifth patient in a phase II study that is being conducted with ibrutinib in patients suffering from relapsed or refractory...(read more)
(Wall Street Sector Selector,
6/7/11)
The market was quite ugly on Tuesday. However, there are some stocks still acting well, or consolidating bullishly, so we’re going to take a look at the long side. They’re getting oversold so there may be some sort of snapback in the...
Pharmacyclics (PCYC) Company Overview
There is no analysis for PCYC yet. But you can go to Wikinvest to help create one!
